HENRY A. WAXMAN, CALIFORNIA EDWARD J. MARKEY, MASSACHUSETTS RICK BOUCHER, VIRGINIA EDOLPHUS TOWNS, NEW YORK FRANK PALLONE, J.R., NEW JERSEY BART GORDON, TENNESSEE BOBBY L. RUSH, ILLINOIS ANNA G. ESHOO, CALIFORNIA BART STUPAK, MICHIGAN ELIOT L. ENGEL, NEW YORK ALBERT R. WYNN, MARYLAND GENE GREEN, TEXAS DIANA DEGETTE, COLORADO VICE CHAIRMAN LOIS CAPPS, CALIFORNIA MIKE DOYLE, PENNSYLVANIA JANE HARMAN, CALIFORNIA TOM ALLEN, MAINE JAN SCHAKOWSKY, ILLINOIS HILDA L. SOLIS, CALIFORNIA CHARLES A. GONZALEZ, TEXAS JAY INSLEE, WASHINGTON TAMMY BALDWIN, WISCONSIN MIKE ROSS, ARKANSAS DARLENE HOOLEY, OREGON ANTHONY D. WEINER, NEW YORK JIM MATHESON, UTAH G.K. BUTTERFIELD, NORTH CAROLINA CHARLIE MELANCON, LOUISIANA JOHN BARROW, GEORGIA BARON P. HILL, INDIANA

DENNIS B. FITZGIBBONS, CHIEF OF STAFF GREGG A. ROTHSCHILD, CHIEF COUNSEL ONE HUNDRED TENTH CONGRESS

U.S. House of Representatives Committee on Energy and Commerce Washington, DC 20515-6115

JOHN D. DINGELL, MICHIGAN CHAIRMAN JOE BARTON, TEXAS
RANKING MEMBER
RALPH M. HALL, TEXAS
FRED UPTON, MICHIGAN
CLIFF STEARNS, FLORIDA
NATHAN DEAL, GEORGIA
ED WHITFIELD, KENTUCKY
BARBARA CUBIN, WYOMING
JOHN SHIMKUS, ILLINOIS
HEATHER WILSON, NEW MEXICO
JOHN B. SHADEGG, ARIZONA
CHARLES W. "CHIP" PICKERING, MISSISSIPPI
VITO FOSSELLA, NEW YORK
ROY BLUNT, MISSOURI
STEVE BUYER, INDIANA
GEORGE RADANOVICH, CALIFORNIA
JOSEPH R. PITTS, PENNSYLVANIA
MARY BOND MACK, CALIFORNIA
GREG WALDEN, OREGON
LEE TERRY, NEBRASKA
MIKE FERGUSON, NEW JERSEY
MIKE ROGERS, MICHIGAN
SUE MYRICK, NORTH CAROLINA
JOHN SULLIVAN, OKLAHOMA
TIM MURPHY, PENNSYLVANIA
MICHAEL C. BURGESS, TEXAS
MARSHA BLACKBURN, TENNESSEE

January 22, 2008

The Honorable Andrew von Eschenbach, M.D. Commissioner
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Dear Dr. von Eschenbach:

Under Rules X and XI of the Rules of the U.S. House of Representatives, the Committee on Energy and Commerce and its Subcommittee on Oversight and Investigations are investigating the use of celebrity endorsements of prescription medications in direct-to-consumer advertising.

We are aware of advertisements for Pfizer's Lipitor with Dr. Robert Jarvik, who appears to state in the advertisement that he takes Lipitor. We are concerned that consumers may misinterpret the health claims of a prescription drug promoted in a direct-to-consumer advertisement utilizing a celebrity physician. In addition, we are concerned that Dr. Jarvik's qualifications may be misinterpreted given that he may not be a practicing physician with a valid license in any State.

We are interested in whether the Food and Drug Administration's Division of Drug Marketing, Advertising, and Communications (DDMAC) has been involved with these Lipitor advertisements.

Therefore, we ask that you provide all records relating to any print, radio, television, or internet advertisements for Lipitor that involve Dr. Jarvik. These records are to include, but not be limited to, any records relating to the review or monitoring of said advertisements, complaints received relating to these advertisements, and any comments or consultations that DDMAC has provided relating to these advertisements.

The Honorable Andrew von Eschenbach, M.D. Page 2

Please deliver copies of the requested records to the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, Room 316, Ford House Office Building, no later than two weeks from the date of this letter. Please note that for the purpose of responding to this request, the terms "record" and "relating" should be interpreted in accordance with the attachment to this letter. After review of the records, we may require additional records and/or interviews with FDA staff.

Thank you for your prompt attention to this matter. If you have any questions relating to this request, please contact us or have your staff contact John F. Sopko or Paul Jung of Committee staff at (202) 226-2424.

Sincerely,

John D. Dingell Chairman

Bart Stupak Chairman

Subcommittee on Oversight and Investigations

Attachment

cc: The Honorable Joe Barton, Ranking Member Committee on Energy and Commerce

The Honorable John Shimkus, Ranking Member Subcommittee on Oversight and Investigations

ATTACHMENT

- 1. The term "records" is to be construed in the broadest sense and shall mean any written or graphic material, however produced or reproduced, of any kind or description, consisting of the original and any non-identical copy (whether different from the original because of notes made on or attached to such copy or otherwise) and drafts and both sides thereof, whether printed or recorded electronically or magnetically or stored in any type of data bank, including, but not limited to, the following: correspondence, memoranda, records. summaries of personal conversations or interviews, minutes or records of meetings or conferences, opinions or reports of consultants, projections, statistical statements, drafts, contracts, agreements, purchase orders, invoices, confirmations, telegraphs, telexes, agendas, books, notes, pamphlets, periodicals, reports, studies, evaluations, opinions, logs, diaries, desk calendars, appointment books, tape recordings, video recordings, emails, voice mails, computer tapes, or other computer stored matter, magnetic tapes, microfilm, microfiche, punch cards, all other records kept by electronic, photographic, or mechanical means, charts, photographs, notebooks, drawings, plans, inter-office communications, intra-office and intra-departmental communications, transcripts, checks and canceled checks, bank statements, ledgers, books, records or statements of accounts, and papers and things similar to any of the foregoing, however denominated.
- 2. The terms "relating," or "relate" as to any given subject means anything that constitutes, contains, embodies, identifies, deals with, or is in any manner whatsoever pertinent to that subject, including but not limited to records concerning the preparation of other records.